SGLT2 agents may reduce cardiovascular risk in diabetics

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Related article: Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study – Circulation (free PDF)

Commentary: SGLT2 Agents Cut CV Events in ‘Real-World’ Analysis – MedPage Today (free registration required) AND Cardiovascular disease and mortality appear lower in patients on SGLT2 inhibitors – ACP Diabetes (free)

Another observational study suggests this class of drugs may reduce cardiovascular mortality and morbidity in patients with diabeties.